Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134403963> ?p ?o ?g. }
- W3134403963 endingPage "2003" @default.
- W3134403963 startingPage "1987" @default.
- W3134403963 abstract "Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov)." @default.
- W3134403963 created "2021-03-15" @default.
- W3134403963 creator A5001985488 @default.
- W3134403963 creator A5006689334 @default.
- W3134403963 creator A5011645185 @default.
- W3134403963 creator A5016138981 @default.
- W3134403963 creator A5018048721 @default.
- W3134403963 creator A5021098925 @default.
- W3134403963 creator A5021528356 @default.
- W3134403963 creator A5022520524 @default.
- W3134403963 creator A5022522496 @default.
- W3134403963 creator A5042432109 @default.
- W3134403963 creator A5043526996 @default.
- W3134403963 creator A5046526239 @default.
- W3134403963 creator A5047384785 @default.
- W3134403963 creator A5049230560 @default.
- W3134403963 creator A5049413660 @default.
- W3134403963 creator A5052046806 @default.
- W3134403963 creator A5058384217 @default.
- W3134403963 creator A5069712875 @default.
- W3134403963 creator A5082712392 @default.
- W3134403963 creator A5086115833 @default.
- W3134403963 creator A5086403929 @default.
- W3134403963 creator A5089930850 @default.
- W3134403963 creator A5091396091 @default.
- W3134403963 creator A5091713884 @default.
- W3134403963 date "2021-06-01" @default.
- W3134403963 modified "2023-09-25" @default.
- W3134403963 title "Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design" @default.
- W3134403963 cites W1661103064 @default.
- W3134403963 cites W1982877913 @default.
- W3134403963 cites W1987230872 @default.
- W3134403963 cites W1990779902 @default.
- W3134403963 cites W2002048624 @default.
- W3134403963 cites W2016789384 @default.
- W3134403963 cites W2020298011 @default.
- W3134403963 cites W2022580424 @default.
- W3134403963 cites W2042990006 @default.
- W3134403963 cites W2055056105 @default.
- W3134403963 cites W2057903858 @default.
- W3134403963 cites W2058089640 @default.
- W3134403963 cites W2091630088 @default.
- W3134403963 cites W2105826859 @default.
- W3134403963 cites W2109541355 @default.
- W3134403963 cites W2113073012 @default.
- W3134403963 cites W2115525561 @default.
- W3134403963 cites W2117716734 @default.
- W3134403963 cites W2118546263 @default.
- W3134403963 cites W2136313650 @default.
- W3134403963 cites W2140579395 @default.
- W3134403963 cites W2145345130 @default.
- W3134403963 cites W2166992787 @default.
- W3134403963 cites W2210073947 @default.
- W3134403963 cites W2216303864 @default.
- W3134403963 cites W2346987786 @default.
- W3134403963 cites W2413971556 @default.
- W3134403963 cites W2414278460 @default.
- W3134403963 cites W2422962677 @default.
- W3134403963 cites W2460376887 @default.
- W3134403963 cites W2486629951 @default.
- W3134403963 cites W2512106959 @default.
- W3134403963 cites W2523798870 @default.
- W3134403963 cites W2532841680 @default.
- W3134403963 cites W2562243521 @default.
- W3134403963 cites W2588220165 @default.
- W3134403963 cites W2588277662 @default.
- W3134403963 cites W2597641129 @default.
- W3134403963 cites W2610269487 @default.
- W3134403963 cites W2618466363 @default.
- W3134403963 cites W2726405642 @default.
- W3134403963 cites W2767256995 @default.
- W3134403963 cites W2770457793 @default.
- W3134403963 cites W2793224908 @default.
- W3134403963 cites W2799309776 @default.
- W3134403963 cites W2807748927 @default.
- W3134403963 cites W2811293382 @default.
- W3134403963 cites W2886837533 @default.
- W3134403963 cites W2890436368 @default.
- W3134403963 cites W2898290601 @default.
- W3134403963 cites W2899675310 @default.
- W3134403963 cites W2901760736 @default.
- W3134403963 cites W2921533600 @default.
- W3134403963 cites W2923666301 @default.
- W3134403963 cites W2944998868 @default.
- W3134403963 cites W2946967142 @default.
- W3134403963 cites W2947681793 @default.
- W3134403963 cites W2950071015 @default.
- W3134403963 cites W2952039293 @default.
- W3134403963 cites W2954359357 @default.
- W3134403963 cites W2962324833 @default.
- W3134403963 cites W2970536272 @default.
- W3134403963 cites W2975075750 @default.
- W3134403963 cites W2983623050 @default.
- W3134403963 cites W2984661502 @default.
- W3134403963 cites W2995373288 @default.
- W3134403963 cites W2995934717 @default.
- W3134403963 cites W3006655689 @default.
- W3134403963 cites W3022297454 @default.